Genfit’s Revenue Surge Driven by Key Milestone

Genfit SA (GNFT) has released an update.

Genfit SA, a biopharmaceutical company, reported a significant revenue increase to €59.7 million for the first nine months of 2024, largely due to a milestone payment from Ipsen following the U.S. launch of Iqirvo for liver disease treatment. The company’s cash reserves also grew to €96.0 million as of September 2024, bolstered by its collaborative efforts in drug development. Genfit’s financial performance highlights its growing influence in the treatment of rare liver diseases.

For further insights into GNFT stock, check out TipRanks’ Stock Analysis page.